LLY
Price
$932.06
Change
+$21.37 (+2.35%)
Updated
Oct 11 closing price
17 days until earnings call
NVS
Price
$116.22
Change
+$1.41 (+1.23%)
Updated
Oct 11 closing price
17 days until earnings call
Ad is loading...

LLY vs NVS

Header iconLLY vs NVS Comparison
Open Charts LLY vs NVSBanner chart's image
Eli Lilly & Co
Price$932.06
Change+$21.37 (+2.35%)
Volume$2.29M
CapitalizationN/A
Novartis AG
Price$116.22
Change+$1.41 (+1.23%)
Volume$1.1M
CapitalizationN/A
View a ticker or compare two or three
LLY vs NVS Comparison Chart
Loading...
LLY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
LLY vs. NVS commentary
Oct 13, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LLY is a Buy and NVS is a StrongBuy.

COMPARISON
Comparison
Oct 13, 2024
Stock price -- (LLY: $932.06 vs. NVS: $116.22)
Brand notoriety: LLY: Notable vs. NVS: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: LLY: 78% vs. NVS: 109%
Market capitalization -- LLY: $739.66B vs. NVS: $197.93B
LLY [@Pharmaceuticals: Major] is valued at $739.66B. NVS’s [@Pharmaceuticals: Major] market capitalization is $197.93B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LLY’s FA Score shows that 3 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).

  • LLY’s FA Score: 3 green, 2 red.
  • NVS’s FA Score: 3 green, 2 red.
According to our system of comparison, both LLY and NVS are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LLY’s TA Score shows that 5 TA indicator(s) are bullish while NVS’s TA Score has 6 bullish TA indicator(s).

  • LLY’s TA Score: 5 bullish, 4 bearish.
  • NVS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both LLY and NVS are a good buy in the short-term.

Price Growth

LLY (@Pharmaceuticals: Major) experienced а +5.06% price change this week, while NVS (@Pharmaceuticals: Major) price change was +1.99% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.02%. For the same industry, the average monthly price growth was -0.06%, and the average quarterly price growth was +8.84%.

Reported Earning Dates

LLY is expected to report earnings on Jan 30, 2025.

NVS is expected to report earnings on Jan 31, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-0.02% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LLY($740B) has a higher market cap than NVS($198B). LLY has higher P/E ratio than NVS: LLY (131.13) vs NVS (23.38). LLY YTD gains are higher at: 60.673 vs. NVS (19.501). NVS has higher annual earnings (EBITDA): 18.3B vs. LLY (8.57B). NVS has more cash in the bank: 14B vs. LLY (2.93B). LLY (25.2B) and NVS (26.3B) have identical debt. NVS has higher revenues than LLY: NVS (46.7B) vs LLY (34.1B).
LLYNVSLLY / NVS
Capitalization740B198B374%
EBITDA8.57B18.3B47%
Gain YTD60.67319.501311%
P/E Ratio131.1323.38561%
Revenue34.1B46.7B73%
Total Cash2.93B14B21%
Total Debt25.2B26.3B96%
FUNDAMENTALS RATINGS
LLY vs NVS: Fundamental Ratings
LLY
NVS
OUTLOOK RATING
1..100
2868
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
16
Undervalued
PROFIT vs RISK RATING
1..100
29
SMR RATING
1..100
1828
PRICE GROWTH RATING
1..100
4549
P/E GROWTH RATING
1..100
2981
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVS's Valuation (16) in the Pharmaceuticals Major industry is significantly better than the same rating for LLY (92). This means that NVS’s stock grew significantly faster than LLY’s over the last 12 months.

LLY's Profit vs Risk Rating (2) in the Pharmaceuticals Major industry is in the same range as NVS (9). This means that LLY’s stock grew similarly to NVS’s over the last 12 months.

LLY's SMR Rating (18) in the Pharmaceuticals Major industry is in the same range as NVS (28). This means that LLY’s stock grew similarly to NVS’s over the last 12 months.

LLY's Price Growth Rating (45) in the Pharmaceuticals Major industry is in the same range as NVS (49). This means that LLY’s stock grew similarly to NVS’s over the last 12 months.

LLY's P/E Growth Rating (29) in the Pharmaceuticals Major industry is somewhat better than the same rating for NVS (81). This means that LLY’s stock grew somewhat faster than NVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LLYNVS
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
57%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
45%
Bearish Trend 2 days ago
37%
Momentum
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
49%
MACD
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
53%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
49%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
42%
Advances
ODDS (%)
Bullish Trend 4 days ago
72%
Bullish Trend 18 days ago
47%
Declines
ODDS (%)
Bearish Trend 16 days ago
51%
Bearish Trend 5 days ago
42%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
70%
Aroon
ODDS (%)
Bearish Trend 2 days ago
56%
Bearish Trend 2 days ago
25%
View a ticker or compare two or three
Ad is loading...
LLY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X63193.023000747.933600
+1.20%
Bitcoin cryptocurrency
SPY579.583.45
+0.60%
SPDR® S&P 500® ETF Trust
GME20.83-0.08
-0.38%
GameStop Corp
AAPL227.55-1.49
-0.65%
Apple
TSLA217.80-20.97
-8.78%
Tesla

LLY and

Correlation & Price change

A.I.dvisor indicates that over the last year, LLY has been loosely correlated with NVS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LLY
1D Price
Change %
LLY100%
+2.35%
NVS - LLY
42%
Loosely correlated
+1.23%
OGN - LLY
25%
Poorly correlated
+0.11%
JNJ - LLY
21%
Poorly correlated
+0.59%
ABBV - LLY
21%
Poorly correlated
-0.08%
PFE - LLY
20%
Poorly correlated
-0.61%
More

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been loosely correlated with AZN. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then AZN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
+1.23%
AZN - NVS
48%
Loosely correlated
+0.62%
GSK - NVS
43%
Loosely correlated
-0.97%
RHHBY - NVS
38%
Loosely correlated
+0.80%
SNY - NVS
37%
Loosely correlated
+0.35%
ABBV - NVS
35%
Loosely correlated
-0.08%
More